This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Evaluation and clinical testing of potentially useful therapies for the acquired immunodeficiency syndrome (AIDS) are entering a new phase.
Until now, drugs or other strategies that might be helpful in the treatment of the disease have, by and large, been evaluated by independent investigators, by pharmaceutical companies that have developed possibly useful agents, or in clinical studies at the National Institutes of Health in Bethesda, Md. However, even though much has been accomplished, the number of AIDS cases continues to mount.
As of this month, there are nearly 18,000 reported cases of AIDS with more than 9,000 deaths. So it is being recognized that the efforts to develop strategies for managing AIDS need more focus administratively and scientifically.
The result has been the formation within the Public Health Service of a task force on AIDS. At the moment, it is headed by Walter R. Dowdle, PhD.
"The idea of my
Marwick C. Task force formed to coordinate study, testing of AIDS therapies. JAMA. 1986;255(10):1233–1242. doi:10.1001/jama.1986.03370100015002